ARCH Venture Partners-backed Orbital Therapeutics’ is researching next-generation RNA medicines that offer advantages over currently available therapies. The startup’s three areas of focus are vaccines, protein replacement, and immunomodulation.
Orbital Therapeutics Raises $270M to Bring RNA-Based Medicines to New Heights
